Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (667) 667
Book Review (70) 70
Conference Proceeding (60) 60
Publication (29) 29
Book Chapter (4) 4
Book / eBook (1) 1
Dissertation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (374) 374
index medicus (371) 371
pulmonary hypertension (241) 241
respiratory system (237) 237
female (236) 236
male (229) 229
middle aged (201) 201
adult (176) 176
abridged index medicus (174) 174
hypertension, pulmonary - physiopathology (134) 134
hypertension, pulmonary - drug therapy (129) 129
aged (113) 113
cardiac & cardiovascular systems (98) 98
hypertension (95) 95
treatment outcome (90) 90
pulmonary arterial hypertension (88) 88
survival (84) 84
hypertension, pulmonary - diagnosis (83) 83
arterial-hypertension (78) 78
hypertension, pulmonary - etiology (77) 77
diagnosis (71) 71
risk factors (69) 69
critical care medicine (67) 67
therapy (67) 67
care and treatment (62) 62
prognosis (57) 57
hemodynamics (56) 56
retrospective studies (55) 55
research (51) 51
drug therapy (50) 50
antihypertensive agents - therapeutic use (49) 49
pulmonary arteries (47) 47
hypertension, pulmonary - mortality (45) 45
medicine, general & internal (45) 45
hypertension, pulmonary - therapy (44) 44
bosentan (43) 43
disease (43) 43
adolescent (42) 42
life sciences (42) 42
animals (41) 41
prostacyclin (40) 40
hypertension, pulmonary (39) 39
double-blind method (37) 37
hypertension, pulmonary - epidemiology (37) 37
chronic disease (36) 36
prospective studies (36) 36
mortality (34) 34
mutation (34) 34
surgery (33) 33
familial primary pulmonary hypertension (32) 32
follow-up studies (32) 32
peripheral vascular disease (32) 32
hypertension, pulmonary - genetics (31) 31
endothelin (30) 30
endothelin receptor antagonists (30) 30
lung transplantation (30) 30
young adult (30) 30
calcium-channel blockers (29) 29
health aspects (29) 29
pulmonary/respiratory (29) 29
sildenafil (29) 29
time factors (29) 29
analysis (28) 28
expression (28) 28
case-control studies (27) 27
endarterectomy (27) 27
guidelines (27) 27
double-blind (26) 26
drug therapy, combination (26) 26
epoprostenol (26) 26
heart (26) 26
hypertension, pulmonary - pathology (26) 26
transplantation (26) 26
continuous intravenous epoprostenol (25) 25
registry (25) 25
antihypertensive agents - administration & dosage (24) 24
cardiovascular (24) 24
hypertension, pulmonary - complications (24) 24
patients (24) 24
pulmonary artery - physiopathology (24) 24
registries (24) 24
severity of illness index (24) 24
clinical trials (23) 23
france - epidemiology (23) 23
lung (23) 23
pulmonary embolism (23) 23
aged, 80 and over (22) 22
cardiac catheterization (22) 22
disease progression (22) 22
human health and pathology (22) 22
hypertension, pulmonary - surgery (22) 22
rats (22) 22
sulfonamides - therapeutic use (22) 22
bone morphogenetic protein receptors, type ii - genetics (21) 21
survival rate (21) 21
algorithms (20) 20
pulmonary embolism - diagnosis (20) 20
antihypertensive agents - adverse effects (19) 19
cardiology and cardiovascular medicine (19) 19
epoprostenol - administration & dosage (19) 19
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Selexipag for the Treatment of Pulmonary Arterial Hypertension
by Sitbon, Olivier and Channick, Richard and Chin, Kelly M and Frey, Aline and Gaine, Sean and Galiè, Nazzareno and Ghofrani, Hossein-Ardeschir and Hoeper, Marius M and Lang, Irene M and Preiss, Ralph and Rubin, Lewis J and Di Scala, Lilla and Tapson, Victor and Adzerikho, Igor and Liu, Jinming and Moiseeva, Olga and Zeng, Xiaofeng and Simonneau, Gérald and McLaughlin, Vallerie V and GRIPHON Investigators
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 26, pp. 2522 - 2533
Among over 1100 patients with pulmonary arterial hypertension who received selexipag, an oral selective IP prostacyclin-receptor agonist, or placebo, the risk... 
SURVIVAL | 5 INHIBITOR THERAPY | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | ANTAGONIST | PROSTACYCLIN RECEPTOR AGONIST | TIME | ORAL TREPROSTINIL | Hypertension, Pulmonary - mortality | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Kaplan-Meier Estimate | Hospitalization - statistics & numerical data | Male | Pyrazines - therapeutic use | Disease Progression | Prodrugs - adverse effects | Acetamides - therapeutic use | Pyrazines - adverse effects | Acetamides - adverse effects | Female | Aged | Hypertension, Pulmonary - drug therapy | Prodrugs - therapeutic use | Hypertension, Pulmonary - complications | Clinical trials | Usage | Drug therapy | Pulmonary hypertension | Hypertension | Headache | Jaw | Endothelin | Pulmonary arteries | Lung | Diarrhea | Nausea | Prostacyclin | Patients | Pain | Circulatory system | Phosphodiesterase | Fees & charges | Substance abuse treatment | Statistical analysis | Committees | Drug dosages | Pharmaceuticals | Index Medicus | Abridged Index Medicus | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Reply to frachon
by Simonneau, Gérald and Humbert, Marc
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 05/2018, Volume 197, Issue 10, pp. 1364 - 1365
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Reply to Frachon: Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension: A Missing Chapter of the Story?
by Simonneau, Gérald and Humbert, Marc
American journal of respiratory and critical care medicine, ISSN 1073-449X, 05/2018, Volume 197, Issue 10, pp. 1364 - 1365
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
by Galiè, Nazzareno and Barberà, Joan A and Frost, Adaani E and Ghofrani, Hossein-Ardeschir and Hoeper, Marius M and McLaughlin, Vallerie V and Peacock, Andrew J and Simonneau, Gérald and Vachiery, Jean-Luc and Grünig, Ekkehard and Oudiz, Ronald J and Vonk-Noordegraaf, Anton and White, R. James and Blair, Christiana and Gillies, Hunter and Miller, Karen L and Harris, Julia H.N and Langley, Jonathan and Rubin, Lewis J and Ambition Investigators and AMBITION Investigators
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 9, pp. 834 - 844
Patients with previously untreated pulmonary arterial hypertension who were randomly assigned to combination therapy with ambrisentan and tadalafil had a... 
INHALED ILOPROST | SURVIVAL | TRIAL | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | EPOPROSTENOL | COMBINATION THERAPY | HEART-FAILURE | DOUBLE-BLIND | BOSENTAN | Hypertension, Pulmonary - mortality | Double-Blind Method | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Hypertension, Pulmonary - physiopathology | Male | Hospitalization | Disease Progression | Tadalafil | Phenylpropionates - therapeutic use | Peptide Fragments - blood | Adult | Female | Phenylpropionates - adverse effects | Aged | Hypertension, Pulmonary - drug therapy | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Natriuretic Peptide, Brain - blood | Pyridazines - adverse effects | Pyridazines - therapeutic use | Symptomatology | Care and treatment | Usage | Analysis | Clinical trials | Dosage and administration | Pulmonary hypertension | Ambrisentan | Hypertension | Edema | Brain natriuretic peptide | Headache | Functional morphology | Pulmonary arteries | Lung diseases | Drug therapy | Patients | Clinical outcomes | Index Medicus | Abridged Index Medicus | Drug side effects | Assaigs clínics de medicaments | Efectes secundaris dels medicaments | Hipertensió pulmonar | Drug testing | Life Sciences | Human health and pathology | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial
by Simonneau, Gérald and Rubin, Lewis J and Galiè, Nazzareno and Barst, Robyn J and Fleming, Thomas R and Frost, Adaani E and Engel, Peter J and Kramer, Mordechai R and Burgess, Gary and Collings, Lorraine and Cossons, Nandini and Sitbon, Olivier and Badesch, David B and PACES Study Grp and PACES Study Group
Annals of Internal Medicine, ISSN 0003-4819, 10/2008, Volume 149, Issue 8, pp. 521 - 530
Background: Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patients with pulmonary arterial hypertension.... 
INHALED ILOPROST | SURVIVAL | MEDICINE, GENERAL & INTERNAL | ORAL SILDENAFIL | EFFICACY | TREPROSTINIL | SAFETY | COMBINATION THERAPY | PROSTACYCLIN | BOSENTAN | Piperazines - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Sulfones - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Dyspepsia - chemically induced | Purines - administration & dosage | Hemodynamics - physiology | Walking - physiology | Sildenafil Citrate | Time Factors | Epoprostenol - adverse effects | Adult | Female | Hypertension, Pulmonary - drug therapy | Purines - adverse effects | Drug Therapy, Combination | Headache - chemically induced | Double-Blind Method | Administration, Oral | Piperazines - adverse effects | Antihypertensive Agents - adverse effects | Adolescent | Quality of Life | Aged | Vasodilator Agents - adverse effects | Hypertension, Pulmonary - etiology | Vasodilator Agents - administration & dosage | Epoprostenol - administration & dosage | Sulfones - administration & dosage | Complications and side effects | Epoprostenol | Dosage and administration | Sildenafil | Drug therapy, Combination | Research | Drug therapy | Pulmonary hypertension | Hypertension | Inhibitor drugs | Patients | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension
by Sitbon, Olivier, MD and Delcroix, Marion, MD and Bergot, Emmanuel, MD and Boonstra, Anco B., MD and Granton, John, MD and Langleben, David, MD and Subías, Pilar Escribano, MD and Galiè, Nazzareno, MD and Pfister, Thomas, PhD and Lemarié, Jean-Christophe, MSc and Simonneau, Gérald, MD
American Heart Journal, ISSN 0002-8703, 2014, Volume 167, Issue 2, pp. 210 - 217
Background Continuous infusion of epoprostenol is the treatment of choice in patients with pulmonary arterial hypertension in functional classes III to IV.... 
Cardiovascular | SODIUM | CARDIAC & CARDIOVASCULAR SYSTEMS | NATRIURETIC PEPTIDE | TREPROSTINIL | PROSTACYCLIN | Single-Blind Method | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Familial Primary Pulmonary Hypertension | Male | Treatment Outcome | Hemodynamics - physiology | Exercise Tolerance - drug effects | Patient Satisfaction | Dose-Response Relationship, Drug | Young Adult | Cardiac Catheterization | Adult | Female | Surveys and Questionnaires | Aged | Hemodynamics - drug effects | Hypertension, Pulmonary - drug therapy | Infusions, Intravenous | Epoprostenol - administration & dosage | Medicine, Experimental | Medical research | Care and treatment | Analysis | Pulmonary hypertension | Hypertension | Heart | Heart rate | Heart attacks | Aqueous solutions | Pulmonary arteries | Blood pressure | Drug therapy | Veins & arteries | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension
by Guignabert, Christophe and Phan, Carole and Seferian, Andrei and Huertas, Alice and Tu, Ly and Thuillet, Raphaël and Sattler, Caroline and Hiress, Morane Le and Tamura, Yuichi and Jutant, Etienne-Marie and Chaumais, Marie-Camille and Bouchet, Stéphane and Manéglier, Benjamin and Molimard, Mathieu and Rousselot, Philippe and Sitbon, Olivier and Simonneau, Gérald and Montani, David and Humbert, Marc
Journal of Clinical Investigation, ISSN 0021-9738, 09/2016, Volume 126, Issue 9, pp. 3207 - 3218
Pulmonary arterial hypertension (PAH) is a life-threatening disease that can be induced by dasatinib, a dual Src and BCR-ABL tyrosine kinase inhibitor that is... 
MEDICINE, RESEARCH & EXPERIMENTAL | FIBROBLAST GROWTH FACTOR-2 | CELLS | ENDOTHELIAL DYSFUNCTION | THERAPEUTIC STRATEGY | INDUCED APOPTOSIS | TYROSINE KINASE | ARTERIAL-HYPERTENSION | BCR-ABL | ENDOPLASMIC-RETICULUM STRESS | CHRONIC MYELOID-LEUKEMIA | Reactive Oxygen Species - metabolism | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | E-Selectin - blood | Male | Hypertension, Pulmonary - chemically induced | Hypoxia - metabolism | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Adult | Female | Intercellular Adhesion Molecule-1 - blood | Antineoplastic Agents - pharmacology | Genetic Predisposition to Disease | Imatinib Mesylate - pharmacology | Cells, Cultured | Rats | Mitochondria - metabolism | Vascular Cell Adhesion Molecule-1 - blood | Dasatinib - pharmacology | Animals | Lung - drug effects | Dasatinib - adverse effects | Hemodynamics | Lung - blood supply | Apoptosis | Dasatinib | Research | Health aspects | Pulmonary hypertension | Risk factors | Scholarships & fellowships | Toxicity | Mortality | Rodents | Leukemia | Hypoxia | Grants | Laboratory animals | Experiments | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension
by Jaïs, Xavier, MD and D'Armini, Andrea M., MD and Jansa, Pavel, MD and Torbicki, Adam, MD and Delcroix, Marion, MD and Ghofrani, Hossein A., MD and Hoeper, Marius M., MD and Lang, Irene M., MD and Mayer, Eckhard, MD and Pepke-Zaba, Joanna, MD and Perchenet, Loïc, PhD and Morganti, Adele, MSc and Simonneau, Gérald, MD and Rubin, Lewis J., MD and Benefit Study Grp
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2008, Volume 52, Issue 25, pp. 2127 - 2134
Objectives Our goal was to investigate the effect of treatment with the oral dual endothelin receptor antagonist bosentan on the hemodynamics and exercise... 
Cardiovascular | Internal Medicine | bosentan | pulmonary endarterectomy | operability | hemodynamics | INHALED ILOPROST | CARDIAC & CARDIOVASCULAR SYSTEMS | SILDENAFIL | FOLLOW-UP | THROMBOENDARTERECTOMY | ENDARTERECTOMY | THERAPY | ARTERIAL-HYPERTENSION | OUTCOMES | UP-REGULATION | PARAMETER | Hypertension | Medical colleges | Care and treatment | Micropollutants | Endothelin | Respiratory tract diseases | Antitubercular agents | Cardiology | Public health | Personal video recorders | Natriuretic peptides | Tuberculosis | Pulmonary hypertension
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension A New Chapter of the Story
by Simonneau, G and Humbert, M
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, ISSN 1073-449X, 03/2018, Volume 197, Issue 6, pp. 704 - 706
In this issue of the Journal, Zamanian and colleagues (pp. 788-800) present the results from a prospective cohort study of patients with pulmonary arterial... 
METHAMPHETAMINE | FENFLURAMINE DERIVATIVES | RESPIRATORY SYSTEM | CRITICAL CARE MEDICINE | Drugs | Anorexia | Methamphetamines | Pulmonary arteries | Medical prognosis | Mutation | Health risk assessment | Pulmonary hypertension
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Pulmonary vascular disorders
by Humbert, Marc, 1963 and Souza, Rogerio and Simonneau, Gérald
2012, Progress in respiratory research, ISBN 9783805599153, Volume 41.
Vascular Diseases | Hypertension, Pulmonary
Web Resource
Details down arrow
11. Full Text Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
by Coghlan, John Gerry and Galiè, Nazzareno and Barberà, Joan Albert and Frost, Adaani E and Ghofrani, Hossein-Ardeschir and Hoeper, Marius M and Kuwana, Masataka and McLaughlin, Vallerie V and Peacock, Andrew J and Simonneau, Gérald and Vachiéry, Jean-Luc and Blair, Christiana and Gillies, Hunter and Miller, Karen L and Harris, Julia H N and Langley, Jonathan and Rubin, Lewis J and AMBITION Investigators and AMBITION investigators
Annals of the Rheumatic Diseases, ISSN 0003-4967, 07/2017, Volume 76, Issue 7, pp. 1219 - 1227
BackgroundPatients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), in particular systemic sclerosis (SSc), had an... 
Systemic Sclerosis | Arterial Hypertension | Treatment | MORTALITY | METAANALYSIS | RHEUMATOLOGY | SYSTEMIC-SCLEROSIS | Lupus Erythematosus, Systemic - complications | Double-Blind Method | Humans | Middle Aged | Male | Antihypertensive Agents - therapeutic use | Disease Progression | Phenylpropionates - therapeutic use | Mixed Connective Tissue Disease - complications | Scleroderma, Systemic - complications | Adult | Female | Aged | Hypertension, Pulmonary - drug therapy | Phosphodiesterase 5 Inhibitors - therapeutic use | Edema - chemically induced | Drug Therapy, Combination | Tadalafil - therapeutic use | Hypertension, Pulmonary - etiology | Pyridazines - therapeutic use | Tadalafil | Usage | Care and treatment | Analysis | Clinical trials | Drug therapy, Combination | Research | Pulmonary hypertension | Heart | Hypertension | Edema | Laboratories | Pulmonary arteries | Mortality | Lung diseases | Cardiovascular disease | Sclerosis | Studies | Systemic sclerosis | Medical prognosis | Population | Health risk assessment | Scleroderma | Index Medicus | Clinical and Epidemiological Research | 1506
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Ambrisentan Therapy for Pulmonary Arterial Hypertension
by Galié, Nazzareno and Badesch, David and Oudiz, Ronald and Simonneau, Gérald and McGoon, Michael D and Keogh, Anne M and Frost, Adaani E and Zwicke, Diane and Naeije, Robert and Shapiro, Shelley and Olschewski, Horst and Rubin, Lewis J
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2005, Volume 46, Issue 3, pp. 529 - 535
The purpose of this study was to examine the efficacy and safety of four doses of ambrisentan, an oral endothelin type A receptor-selective antagonist, in... 
CARDIAC & CARDIOVASCULAR SYSTEMS | RECEPTOR ANTAGONIST BOSENTAN | ENDOTHELIN-1 | Hypertension, Pulmonary - diagnosis | Follow-Up Studies | Humans | Middle Aged | Male | Reference Values | Hemodynamics - physiology | Exercise Tolerance - drug effects | Dose-Response Relationship, Drug | Vascular Resistance - drug effects | Adult | Female | Phenylpropionates - adverse effects | Hypertension, Pulmonary - drug therapy | Severity of Illness Index | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Phenylpropionates - administration & dosage | Probability | Treatment Outcome | Pyridazines | Maximum Tolerated Dose | Aged | Hemodynamics - drug effects | Hypertension | Medical colleges | Care and treatment | Micropollutants | Public health | Personal video recorders | Pulmonary hypertension | Disease | Pulmonary arteries | Human immunodeficiency virus--HIV | Collagen | Smooth muscle | Infections | Muscular system | Drug therapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
by Pulido, Tomás and Adzerikho, Igor and Channick, Richard N and Delcroix, Marion and Galiè, Nazzareno and Ghofrani, Hossein-Ardeschir and Jansa, Pavel and Jing, Zhi-Cheng and Le Brun, Franck-Olivier and Mehta, Sanjay and Mittelholzer, Camilla M and Perchenet, Loïc and Sastry, B.K.S and Sitbon, Olivier and Souza, Rogério and Torbicki, Adam and Zeng, Xiaofeng and Rubin, Lewis J and Simonneau, Gérald and SERAPHIN Investigators
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 9, pp. 809 - 818
In an event-driven trial, macitentan (an endothelin-receptor antagonist) at a dose of 3 or 10 mg was compared with placebo in patients with symptomatic... 
INHALED ILOPROST | MEDICINE, GENERAL & INTERNAL | SILDENAFIL | TREPROSTINIL | EPOPROSTENOL | AMBRISENTAN THERAPY | 6-MINUTE WALK DISTANCE | DOUBLE-BLIND | BOSENTAN | Hypertension, Pulmonary - mortality | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Hospitalization - statistics & numerical data | Familial Primary Pulmonary Hypertension | Male | Endothelin B Receptor Antagonists | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Endothelin A Receptor Antagonists | Exercise Tolerance | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Adult | Female | Hypertension, Pulmonary - drug therapy | Hypertension, Pulmonary - complications | Research | Pharmacokinetics | Drug therapy | Pulmonary hypertension | Hypertension | Heart failure | Headache | Substance abuse treatment | Intravenous administration | Endothelin | Laboratories | Syngeneic grafts | Mortality | Lung transplantation | Clinical trials | Rhinopharyngitis | Patients | Morbidity | Clinical outcomes | Prostaglandins | Intubation | Drug dosages | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights